The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services.
- In a report released on October 10, Scotiabank also assigned a Buy rating to the stock with a $47.00 price target.
- Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics.
- It’s calculated by averaging the closing stock price over the previous 50 trading days.
- The precision oncology leader benefited from a pair of positive analyst notes this week.
- Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.
It attempts to reflect the cash profit generated by a company’s operations. 52 week low is the lowest price of a stock in the past 52 weeks, or one year. Guardant Health Inc 52 week low is $20.67 as of October 14, 2023. 52 week high is the highest price of a stock in the past 52 weeks, or one year. Guardant Health Inc 52 week high is $54.47 as of October 14, 2023. When looking for the best stocks to buy and watch, focus on those with rising relative price strength.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Guardant Health with a $48.56 average price target, a 71.35% upside from current levels.
The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA. The Price-to-Earnings intelligent ecommerce personalization for retailers (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS).
In a report released on October 10, Scotiabank also assigned a Buy rating to the stock with a $47.00 price target. Guardant Health issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $545.00 million-$550.00 million, compared to the consensus revenue estimate of $541.39 million. According to 14 analysts, the average rating for GH stock is “Strong Buy.” The 12-month stock price forecast is $54.79, which is an increase of 102.70% from the latest price.
– Provides non-invasive cancer diagnostics and a comprehensive genomic and liquid biopsy.
Since then, GH stock has decreased by 0.6% and is now trading at $27.03. USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm … Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
FTC Challenge of Illumina’s Cancer-Screening Acquisition Rejected by Judge
Their GH share price forecasts range from $34.00 to $88.00. On average, they predict the company’s share price to fxcm broker review reach $55.44 in the next twelve months. This suggests a possible upside of 105.1% from the stock’s current price.
Exact Sciences Stock Falls After Earnings. Here’s What Wall Street Is Saying.
The consensus among Wall Street research analysts is that investors should “buy” GH shares. The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods.
Investor Email Alerts
In a report released today, Alexander Nowak from Craig-Hallum maintained a Buy rating on Guardant Health (GH – Research Report). GH, +2.46% shares fell in the extended session Monday after the cancer testing company announced a secondary offering of its stock. The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is neutral on the stock.
MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since… Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
It can also be calculated by dividing the company’s Market Cap by the Net Profit. There’s big news for Guardant Health (GH 1.35%) shareholders today — but disappointing news also. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free bdswiss review guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation. Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. In 2022, the United States accounted for 94% of revenue, and other markets the remaining 6%.
You must click the activation link in order to complete your subscription. Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Guardant Health.
Data may be intentionally delayed pursuant to supplier requirements. 52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company’s employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. Guardant Health’s stock was trading at $27.20 at the beginning of the year.